Abstract 523P
Background
Chemo-immunotherapy is the standard first-line (1L) therapy for patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). However, not all ES-SCLC pts benefit from chemo-immunotherapy. We aimed to assess the efficacy and safety of camrelizumab + apatinib as maintenance treatment for ES-SCLC pts who had disease control after standard 1L chemotherapy.
Methods
Key inclusion criteria were age 18-75 years, histologically or cytologically confirmed ES-SCLC, ECOG PS 0-1, no disease progression after 4∼6 cycles of standard 1L chemotherapy. Eligible pts received camrelizumab (200mg, iv, d1, q3w) + apatinib (250mg, po, qd) until disease progression or intolerable toxicity. The primary endpoint was progression free survival (PFS); key secondary endpoints included overall response rate (ORR), disease control rate (DCR) and safety.
Results
From July 2021 to July 2023, 18 pts who received at least 1 dose of camrelizumab + apatinib were analyzed. The median age was 59 years (range: 45-75) with 16 (88.9%) males, 11 (61.1%) former smokers, 4 (22.2%) current smokers and 13 (72.2%) with ECOG PS 1. One patient (5.6%) had brain metastasis, 3 (16.7%) had liver metastasis, and 4 (22.2%) had bone metastasis. At data cutoff, 5 pts remained on treatment, and 16 pts had at least 1 post-treatment tumor assessment. The median PFS was 6.4 months (3.0-NR), the confirmed ORR and DCR were 12.5% (2/16) and 100% (16/16), respectively. Treatment-related adverse events (TRAEs) were reported in 17 pts (94.4%). Among them, 10 (55.6%) pts experienced grade 3 or 4 TRAEs. This included 2 pts (11.1%) with diarrhea, 2 (11.1%) with hyperglycemia, and 1 patient each (5.6%) with increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocyte count, pancreatitis, hyponatremia, asthenia, elevated γ-glutamyl transferase and nerve injury. No grade 5 adverse events occurred.
Conclusions
Camrelizumab plus apatinib had promising efficacy and acceptable safety as maintenance treatment in ES-SCLC pts who responded or had stable disease after standard 1L chemotherapy. Further validation is warranted.
Clinical trial identification
NCT04901754.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract